Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Recurrent Glioblastoma is a type of brain tumor that has returned after previous treatment. The study uses a personalized vaccine made from the patient’s own immune cells called dendritic cells, which are grown in the lab and then “loaded” with a preparation of the patient’s own tumor material (tumor lysate). This means the vaccine is created from the patient’s own tissue, and the dendritic cells act like teachers that show the immune system what the cancer looks like so it can learn to attack it. In addition, the trial includes an intravenous medication called atezolizumab, which blocks a protein known as PD‑L1 that tumors use to hide from the immune system, thereby helping immune cells stay active against the cancer.
The purpose of the study is to determine whether the vaccine alone or together with atezolizumab can trigger a tumor‑fighting immune response. Participants receive a series of small injections of the vaccine under the skin over several weeks, along with occasional IV infusions of atezolizumab. Blood samples are taken at various times to check for signs that the immune system is responding, and doctors monitor for any side effects. Follow‑up visits continue for several months to assess overall health and disease status.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
12 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a personalized cancer vaccine made from the patient’s own immune cells. Doctors collect dendritic cells, which help the immune system recognize threats, and then load them with tiny pieces of the patient’s tumor. After the cells are prepared, they are injected into the skin. This vaccine is meant to teach the immune system to spot and attack the glioblastoma cells when they appear again.
is a medication that blocks a protein called PD‑L1, which some cancers use to hide from the immune system. By blocking this protein, atezolizumab helps the body’s T‑cells stay active and better able to fight the tumor. It is given through an IV infusion and is used in the study together with the dendritic cell vaccine to see if the combination improves the anti‑tumor response.
The vaccine is given as a 2.5 ml intradermal injection, where a patient’s own mature dendritic cells are mixed with a preparation of the patient’s tumor tissue and then injected into the skin. It is still an experimental therapy and is being studied in clinical trials, with no regulatory approval yet. It is being tested for recurrent glioblastoma and works by presenting tumor pieces to the immune system so T‑cells can recognize and attack the cancer. It belongs to the class of therapeutic cancer vaccines and cell‑based immunotherapies.
Atezolizumab is given as an intravenous infusion of 1200 mg, usually over 30–60 minutes. It is an approved drug for several cancers such as bladder and lung cancer, and its use in glioblastoma is currently being studied in clinical trials. The drug belongs to the class of immune checkpoint inhibitors and is a monoclonal antibody that blocks the protein PD‑L1. By blocking PD‑L1, it prevents the cancer from turning off T‑cells, allowing the immune system to attack the tumor.
Other trials in this disease – keep exploring while you decide
Hungary
Italy
Norway
Belgium
DenmarkNorwaysourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
